Antiparkinsonian Drugs and Mechanisms of Action

Because dopamine itself cannot cross the blood-brain barrier, levodopa (a biological precursor) is administered. However, levodopa is rapidly broken down by the enzyme dopa decarboxylase in the periphery, which can cause significant side effects like nausea and cardiac dysrhythmias. To prevent this, carbidopa is administered as an adjunct; it is a peripheral decarboxylase inhibitor that prevents the breakdown of levodopa before it reaches the brain, allowing for lower, more effective doses.

Clinical Note: Levodopa-carbidopa is often started as soon as patients are unable to function, but it requires careful titration. The goal is to achieve maximal benefit without inducing dyskinesia, which is a sign of toxicity.

Indirect-Acting Dopaminergic Drugs

Indirect-acting drugs do not stimulate the receptors themselves but instead influence the metabolism of existing catecholamines (dopamine, norepinephrine, and epinephrine) to increase their availability in the CNS.

MAO-B Inhibitors

Monoamine oxidase (MAO) is an enzyme responsible for the breakdown of catecholamines. While nonselective MAOIs affect both MAO-A and MAO-B, selective MAO-B inhibitors like selegiline and rasagiline are used to increase dopaminergic stimulation in the brain with a lower risk of the "cheese effect" (hypertension caused by tyramine-rich foods).

These drugs are frequently used as adjunctive therapy to help manage symptom fluctuations and can delay the necessity of levodopa therapy in the early stages of the disease.

COMT Inhibitors

Entacapone is a COMT (catechol ortho-methyltransferase) inhibitor used to treat symptom fluctuations in patients on levodopa-carbidopa. By inhibiting the enzyme that metabolizes levodopa, entacapone delays the "off" periods (when medication effectiveness wanes) and has a "dose-sparing" effect.

Patient Education Tip: Patients taking entacapone should be informed that their urine may turn a brownish-orange color; this is a harmless side effect.

Dopamine Modulators and Anticholinergics

Other classes of drugs are used to target specific symptoms or to balance the neurotransmitter ratio:

• Dopamine Modulators: Amantadine is used in early to moderate stages to reduce tremors and muscle rigidity.
• Anticholinergic Drugs: Drugs like benztropine are used as secondary treatments to manage tremors and muscle rigidity by antagonizing the excessive acetylcholine activity that occurs when dopamine is low.

Managing Motor Complications and Drug Interactions

As Parkinson's disease progresses, the therapeutic window for medications narrows, leading to complex motor complications.

Dyskinesia and Motor Fluctuations

• Dyskinesia: These are abnormal, involuntary movements (such as chorea or dystonia) that often occur as an adverse effect of long-term levodopa therapy.
• On-Off Phenomenon: Patients may experience unpredictable swings between periods of good symptomatic control ("on" time) and periods of poor control ("off" time).
• Wearing-off Phenomenon: This is a gradual worsening of symptoms as the medication's effect diminishes before the next dose is due.

Drug Interactions

Careful monitoring of drug interactions is vital for patient safety:

1. MAO-B Inhibitors: Must avoid concurrent use with meperidine (an opioid) due to the risk of severe interactions.
2. Levodopa-Carbidopa: High protein diets can interfere with the absorption of levodopa. Additionally, pyridoxine (Vitamin $\text{B}_{6}$) can reduce the effectiveness of the drug.
3. Catecholamine Metabolism: Combining COMT inhibitors with other MAOIs or catecholamines can lead to tachycardia and hypertension.

Exam Tip: If a patient is experiencing "off" periods where their medication seems to stop working before the next dose, the addition of a COMT inhibitor like entacapone is a common therapeutic strategy to maximize "on" time.